Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.
Author:
Publish date:

President Trump recently criticized the FDA approval process as "slow and burdensome" but failed to offer up specific plans for reform. If FDA standards were to be altered, the market could see an avalanche of new drugs and treatments. TheStreet'sAdam Feuerstein compiled the "Gnarly Nine" companies that could be interesting to watch as the FDA enters the Trump era. 

    Alkermes

    CytRX

    Dynavax Technologies

    Intra-Cellular Therapies

    Novan

    Portola Pharmaceuticals

    PTC Therapeutics

    Rigel Pharmaceuticals

    TG Therapeutics

    READ THE FULL STORY HERE:

    These 'Gnarly 9' Biotechs Will Test the FDA's Mettle

    This article was written by a staff member of TheStreet.